Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 in advanced solid tumors
NCT06081907Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), melanoma, sponsored by Hunan Cancer Hospital. Started Dec 2023; status: recruiting.
02
Drugs
IBI363
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT06081907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081907.